U.S. Markets open in 7 hrs 39 mins
  • S&P Futures

    4,280.75
    -60.75 (-1.40%)
     
  • Dow Futures

    33,641.00
    -414.00 (-1.22%)
     
  • Nasdaq Futures

    13,918.00
    -240.50 (-1.70%)
     
  • Russell 2000 Futures

    1,932.90
    -39.80 (-2.02%)
     
  • Crude Oil

    86.59
    -0.76 (-0.87%)
     
  • Gold

    1,810.60
    -19.10 (-1.04%)
     
  • Silver

    23.23
    -0.58 (-2.44%)
     
  • EUR/USD

    1.1222
    -0.0023 (-0.2020%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • Vix

    31.96
    +0.80 (+2.57%)
     
  • GBP/USD

    1.3426
    -0.0037 (-0.2725%)
     
  • USD/JPY

    114.7000
    +0.0400 (+0.0349%)
     
  • BTC-USD

    36,092.50
    -1,335.29 (-3.57%)
     
  • CMC Crypto 200

    821.65
    -34.17 (-3.99%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    26,170.30
    -841.00 (-3.11%)
     

BMRA: InFoods Clinical Trial Advances, Further Step Towards Potential FDA Clearance

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • BMRA

By M. Marin

NASDAQ:BMRA

READ THE FULL BMRA RESEARCH REPORT

Last week, Biomerica (NASDAQ:BMRA) announced that it is nearing completion of patient enrollment in the InFoods® IBS endpoint clinical trial. As a diagnostic-guided therapy (not a drug), InFoods does not have the side effects drugs often have and can be used alone and/or as part of a drug therapy program.

Patient enrollments are expected to be completed by the end of April 2021 and BMRA is optimistic that results from the endpoint trial will lead to potential partnership discussions with health sciences, Big Pharma and medical device companies. The study also advances inFoods on the path to potential FDA clearance following a subsequent final pivotal trial.

Earlier this year, BMRA received a 2nd U.S. patent for InFoods, which we believe expands the potential applications and use of the inFoods platform. In the U.S., IBS-related diseases impact an estimated 45+ million people (according to IFFGD) and the total direct plus indirect annual domestic cost of IBS has been estimated at $30 billion, according to the Journal of American Managed Care.

Separately, BMRA’s focus in 2020 has included extending its expertise and technology to develop and commercialize COVID-19 diagnostics. The company has developed two types of serological diagnostic tests for COVID-19, a rapid diagnostic test (RDT) and an enzyme-linked immunosorbent assay (ELISA), and is also developing an antigen test. We believe this both creates a new revenue stream and also offers proof-of-concept of the versatility and applicability of the company’s technology and IP. BMRA has been shipping in the EU following receipt of the required CE mark, leveraging its existing distribution network.

BMRA hired Steve Sloan, an experienced industry executive, to assume the role of CFO following the recent retirement of its longstanding CFO. He has extensive industry experience and management is optimistic that he can help support the company’s anticipated growth as it advances inFoods and extends its expertise and technologies to other applications, as it has done with the recent introduction of COVID-19 diagnostic tests.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.